Medscape is available in 5 Language Editions – Choose your Edition here.


Normal Pressure Hydrocephalus Treatment & Management

  • Author: Michael J Schneck, MD, MBA; Chief Editor: Selim R Benbadis, MD  more...
Updated: Jul 12, 2016

Medical Care

A levodopa challenge may be helpful to rule out idiopathic Parkinson disease. Patients with normal pressure hydrocephalus (NPH) have no significant response to levodopa or dopamine agonists.


Surgical Care

Surgical CSF shunting remains the main treatment modality. Prior to embarking upon surgical therapy, knowing which patients may benefit from surgery is necessary. Detailed testing is performed before and after CSF drainage.

Initially, patients are given a baseline neuropsychological evaluation (eg, Folstein test or formal neuropsychological evaluation) and a timed walking test. Patients then undergo a lumbar puncture with removal of approximately 50 mL of CSF. Testing is then repeated 3 hours later. A clear-cut improvement in mental status and/or gait predicts a favorable response to shunt surgery. Improvement in gait may be seen in the form of reduced time to walk a fixed distance, reduced gait apraxia, or reduced freezing of gait. Videotaping the gait evaluation before and after the large volume lumbar puncture or lumbar drain placement can be helpful in decision making. Reduction in bladder hyperactivity also may be a sign of good outcome from shunting. Occasionally, improvement may be delayed and appear 1-2 days after the large-volume lumbar punctures. For a more objective assessment, videotape the timed walking test before and after lumbar puncture.

While large volume lumbar puncture was the earliest invasive diagnostic test in predicting response to shunt surgery, external lumbar drainage (ELD) is being used with increased frequency. In this method, clinicians use an indwelling CSF catheter in lieu of repeated lumbar punctures. The drainage catheter is generally left in place for 3 days, allowing sufficient time for return of neuronal function.[14] This method carries a higher risk of meningeal infection but may allow for a more accurate prognosis.[15]

In a prospective study of 151 patients with suspected idiopathic NPH, all patients underwent ELD. Patients with clinical improvement after ELD were offered shunt surgery, 90% of whom improved.[16] Others have confirmed the positive predictive value of improvement after ELD.[14, 17] Less clear, however, is the negative predictive value of ELD. In one study, 64% of patients who underwent shunt surgery had improvement, despite a negative ELD result.[18] Thus, given the dramatic improvement in quality of life for shunt responders, some have advocated for less reliance on predictive testing.[19, 20] Given the potential morbidity and mortality of shunt surgery, however, this has not been widely adopted.

An alternative method of predicting response to shunt surgery is CSF infusion testing. In this test, 2 lumbar drains are placed. One drain is used for continuous pressure monitoring while the other drain is used to continuously infuse solution into the CSF space. Elevated pressures during infusion are specific for shunt-responsive NPH. However, due to a lower sensitivity and potential morbidity, this is infrequently used.

Patients with a good response to predictive testing should be considered for ventriculoperitoneal or ventriculoatrial shunting. The best results are reported in patients who have no adverse risk factors; have responded favorably to a large-volume lumbar puncture; and have definite evidence of dementia and ataxia, CT scan or MRI evidence of chronic hydrocephalus, and a normal CSF at lumbar puncture. Some evidence indicates that patients with gait disturbance, mild or no incontinence, and mild dementia fare best among shunt surgery patients.[19, 21]

Another modality without significant current use is isotope cisternography. The method involves injecting a radiolabeled isotope into the CSF space. Using this method, the excretion of the isotope can be monitored. Lack of visualization of the isotope over the brain (ie, impaired absorption of the arachnoid villa) suggests a diagnosis of NPH. This test is rarely used due to the low positive predictive value with regards to shunt-responsiveness.

The clinical usefulness of cisternography was evaluated in a large-scale study (n=76) by Vanneste et al.[22] The predictive value of a scale based on combined clinical and CT scan criteria was established first, followed by an assessment of the predictive value of cisternography. Predictions based on cisternograms were identical to those of the clinical/CT scan scale in 43%, better in 24%, and worse in 33%. This suggests that cisternography does not improve the diagnostic accuracy of combined clinical and CT scan criteria in patients with presumed normal pressure hydrocephalus.

In summary, an ideal candidate for shunt surgery would show imaging evidence of ventriculomegaly indicated by a frontal horn ratio exceeding 0.50 on imaging studies along with one or more of the following criteria:

  • Presence of a clearly identified etiology
  • Predominant gait difficulties with mild or absent cognitive impairment
  • Substantial improvement after CSF withdrawal (CSF tap test or lumbar drainage)
  • Normal-sized or occluded sylvian fissures and cortical sulci on CT or MRI
  • Absent or moderate white matter lesions on MRI

An alternative technique to shunt surgery is gaining some currency. This involves endoscopic third ventriculostomy (ETV). Although it has been previously used in noncommunicating hydrocephalus, its use has also been examined in patients with NPH.

One study examining this technique followed a series of 36 patients divided into a group of 29 patients with secondary communicating hydrocephalus and a group of 7 patients with normal pressure hydrocephalus. Sixteen (44.4%) of the patients had a previous ventriculoperitoneal shunt placement that presented with shunt malfunction. ETV was considered successful in 27 of 36 patients (75%). A Kaplan-Meier analysis revealed that the successful proportion of ETVs in secondary communicating hydrocephalus at 0.5, 1, and 3 months of follow-up was 0.83, 0.8, and 0.77, respectively; in the idiopathic NPH group, it was 0.83 initially and became stable at 0.66 after the first month. However, these results need to be replicated with larger series before the use of this technique is determined.[23]



A neurologist should be initially involved in the evaluation of suspected NPH, at which time a lumbar puncture is performed. For appropriate patients, a neurosurgical consultation should also be obtained.

Contributor Information and Disclosures

Michael J Schneck, MD, MBA Vice Chair and Professor, Departments of Neurology and Neurosurgery, Loyola University, Chicago Stritch School of Medicine; Associate Director, Stroke Program, Director, Neurology Intensive Care Program, Medical Director, Neurosciences ICU, Loyola University Medical Center

Michael J Schneck, MD, MBA is a member of the following medical societies: American Academy of Neurology, American Society of Neuroimaging, Stroke Council of the American Heart Association, Neurocritical Care Society

Disclosure: Received honoraria from Boehringer-Ingelheim for speaking and teaching; Received honoraria from Sanofi/BMS for speaking and teaching; Received honoraria from Pfizer for speaking and teaching; Received honoraria from UCB Pharma for speaking and teaching; Received consulting fee from Talecris for other; Received grant/research funds from NMT Medical for independent contractor; Received grant/research funds from NIH for independent contractor; Received grant/research funds from Sanofi for independe.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Nestor Galvez-Jimenez, MD, MSc, MHA The Pauline M Braathen Endowed Chair in Neurology, Chairman, Department of Neurology, Program Director, Movement Disorders, Department of Neurology, Division of Medicine, Cleveland Clinic Florida

Nestor Galvez-Jimenez, MD, MSc, MHA is a member of the following medical societies: American Academy of Neurology, American College of Physicians, International Parkinson and Movement Disorder Society

Disclosure: Nothing to disclose.

Chief Editor

Selim R Benbadis, MD Professor, Director of Comprehensive Epilepsy Program, Departments of Neurology and Neurosurgery, Tampa General Hospital, University of South Florida College of Medicine

Selim R Benbadis, MD is a member of the following medical societies: American Academy of Neurology, American Medical Association, American Academy of Sleep Medicine, American Clinical Neurophysiology Society, American Epilepsy Society

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Cyberonics; Eisai; Lundbeck; Sunovion; UCB; Upsher-Smith<br/>Serve(d) as a speaker or a member of a speakers bureau for: Cyberonics; Eisai; Glaxo Smith Kline; Lundbeck; Sunovion; UCB<br/>Received research grant from: Cyberonics; Lundbeck; Sepracor; Sunovion; UCB; Upsher-Smith.

Additional Contributors

Arif I Dalvi, MD Director, Movement Disorders Center, NorthShore University Health System; Clinical Associate Professor of Neurology, University of Chicago Pritzker Medical School

Arif I Dalvi, MD is a member of the following medical societies: International Parkinson and Movement Disorder Society, European Neurological Society

Disclosure: Nothing to disclose.

Ashvini P Premkumar, MD Associate Director, Movement Disorders Center, NorthShore University HealthSystem, Clinical Instructor of Neurology, University of Chicago Pritzker Medical School

Ashvini P Premkumar, MD is a member of the following medical societies: American Academy of Neurology, International Parkinson and Movement Disorder Society

Disclosure: Nothing to disclose.

  1. Aimard G, Vighetto A, Gabet JY, Bret P, Henry E. [Acetazolamide: an alternative to shunting in normal pressure hydrocephalus? Preliminary results]. Rev Neurol (Paris). 1990. 146(6-7):437-9. [Medline].

  2. Hakim S, Adams RD. The special clinical problem of symptomatic hydrocephalus with normal cerebrospinal fluid pressure. Observations on cerebrospinal fluid hydrodynamics. J Neurol Sci. 1965 Jul-Aug. 2(4):307-27. [Medline].

  3. Brean A, Eide PK. Prevalence of probable idiopathic normal pressure hydrocephalus in a Norwegian population. Acta Neurol Scand. 2008 Jul. 118(1):48-53. [Medline].

  4. Hiraoka K, Meguro K, Mori E. Prevalence of idiopathic normal-pressure hydrocephalus in the elderly population of a Japanese rural community. Neurol Med Chir (Tokyo). 2008 May. 48(5):197-99; discussion 199-200. [Medline].

  5. Tanaka N, Yamaguchi S, Ishikawa H, Ishii H, Meguro K. Prevalence of possible idiopathic normal-pressure hydrocephalus in Japan: the Osaki-Tajiri project. Neuroepidemiology. 2009. 32(3):171-5. [Medline].

  6. Marmarou A, Young HF, Aygok GA. Estimated incidence of normal pressure hydrocephalus and shunt outcome in patients residing in assisted-living and extended-care facilities. Neurosurg Focus. 2007 Apr 15. 22(4):E1. [Medline].

  7. Sakakibara R, Uchiyama T, Kanda T, Uchida Y, Kishi M, Hattori T. [Urinary dysfunction in idiopathic normal pressure hydrocephalus]. Brain Nerve. 2008 Mar. 60(3):233-9. [Medline].

  8. Bech-Azeddine R, Hogh P, Juhler M, Gjerris F, Waldemar G. Idiopathic normal-pressure hydrocephalus: clinical comorbidity correlated with cerebral biopsy findings and outcome of cerebrospinal fluid shunting. J Neurol Neurosurg Psychiatry. 2007 Feb. 78(2):157-61. [Medline].

  9. Golomb J, Wisoff J, Miller DC, et al. Alzheimer's disease comorbidity in normal pressure hydrocephalus: prevalence and shunt response. J Neurol Neurosurg Psychiatry. 2000 Jun. 68(6):778-81. [Medline].

  10. Graff-Radford NR, Godersky JC. Symptomatic congenital hydrocephalus in the elderly simulating normal pressure hydrocephalus. Neurology. 1989 Dec. 39(12):1596-600. [Medline].

  11. Sasaki M, Honda S, Yuasa T, Iwamura A, Shibata E, Ohba H. Narrow CSF space at high convexity and high midline areas in idiopathic normal pressure hydrocephalus detected by axial and coronal MRI. Neuroradiology. 2008 Feb. 50(2):117-22. [Medline].

  12. Gyldensted C. Measurements of the normal ventricular system and hemispheric sulci of 100 adults with computed tomography. Neuroradiology. 1977 Dec 31. 14(4):183-92. [Medline].

  13. Singer OC, Melber J, Hattingen E, Jurcoane A, Keil F, Neumann-Haefelin T, et al. MR volumetric changes after diagnostic CSF removal in normal pressure hydrocephalus. J Neurol. 2012 May 17. [Medline].

  14. Williams MA, Razumovsky AY, Hanley DF. Comparison of Pcsf monitoring and controlled CSF drainage diagnose normal pressure hydrocephalus. Acta Neurochir Suppl. 1998. 71:328-30. [Medline].

  15. Governale LS, Fein N, Logsdon J, Black PM. Techniques and complications of external lumbar drainage for normal pressure hydrocephalus. Neurosurgery. 2008 Oct. 63(4 Suppl 2):379-84; discussion 384. [Medline].

  16. Marmarou A, Young HF, Aygok GA, et al. Diagnosis and management of idiopathic normal-pressure hydrocephalus: a prospective study in 151 patients. J Neurosurg. 2005 Jun. 102(6):987-97. [Medline].

  17. Murai R, Hashiguchi F, Kusuyama A, et al. Percutaneous stenting for malignant biliary stenosis. Surg Endosc. 1991. 5(3):140-2. [Medline].

  18. Walchenbach R, Geiger E, Thomeer RT, Vanneste JA. The value of temporary external lumbar CSF drainage in predicting the outcome of shunting on normal pressure hydrocephalus. J Neurol Neurosurg Psychiatry. 2002 Apr. 72(4):503-6. [Medline].

  19. Burnett MG, Sonnad SS, Stein SC. Screening tests for normal-pressure hydrocephalus: sensitivity, specificity, and cost. J Neurosurg. 2006 Dec. 105(6):823-9. [Medline].

  20. Stein SC, Burnett MG, Sonnad SS. Shunts in normal-pressure hydrocephalus: do we place too many or too few?. J Neurosurg. 2006 Dec. 105(6):815-22. [Medline].

  21. Hebb AO, Cusimano MD. Idiopathic normal pressure hydrocephalus: a systematic review of diagnosis and outcome. Neurosurgery. 2001 Nov. 49(5):1166-84; discussion 1184-6. [Medline].

  22. Vanneste J, Augustijn P, Davies GA, Dirven C, Tan WF. Normal-pressure hydrocephalus. Is cisternography still useful in selecting patients for a shunt?. Arch Neurol. 1992 Apr. 49(4):366-70. [Medline].

  23. Rangel-Castilla L, Barber S, Zhang YJ. The role of endoscopic third ventriculostomy in the treatment of communicating hydrocephalus. World Neurosurg. 2012 Mar. 77(3-4):555-60. [Medline].

  24. Vanneste J, Augustijn P, Dirven C, Tan WF, Goedhart ZD. Shunting normal-pressure hydrocephalus: do the benefits outweigh the risks? A multicenter study and literature review. Neurology. 1992 Jan. 42(1):54-9. [Medline].

  25. Boon AJ, Tans JT, Delwel EJ, et al. Dutch Normal-Pressure Hydrocephalus Study: the role of cerebrovascular disease. J Neurosurg. 1999 Feb. 90(2):221-6. [Medline].

  26. Hamilton R, Patel S, Lee EB, Jackson EM, Lopinto J, Arnold SE. Lack of shunt response in suspected idiopathic normal pressure hydrocephalus with Alzheimer disease pathology. Ann Neurol. 2010 Oct. 68(4):535-40. [Medline].

  27. Pujari S, Kharkar S, Metellus P, Shuck J, Williams MA, Rigamonti D. Normal pressure hydrocephalus: long-term outcome after shunt surgery. J Neurol Neurosurg Psychiatry. 2008 Nov. 79(11):1282-6. [Medline].

  28. Hertel F, Zuchner M, Decker C, Schill S, Bosniak I, Bettag M. The Miethke dual switch valve: experience in 169 adult patients with different kinds of hydrocephalus: an open field study. Minim Invasive Neurosurg. 2008 Jun. 51(3):147-53. [Medline].

  29. Brooks M. CSF Protein a Diagnostic Marker for Idiopathic NPH? Medscape Medical News. July 05, 2013. Available at Accessed: July 16, 2013.

  30. Nishida N, Nagata N, Toda H, Ishikawa M, Urade Y, Iwasaki K. L-PGDS could be a surrogate marker of frontal lobe dysfunction in idiopathic NPH [abstract 1014]. Available at Accessed: July 16, 2013.

  31. Tisell M, Hellstrom P, Ahl-Borjesson G, Barrows G, Blomsterwall E, Tullberg M. Long-term outcome in 109 adult patients operated on for hydrocephalus. Br J Neurosurg. 2006 Aug. 20(4):214-21. [Medline].

  32. Tsakanikas D, Relkin N. Normal pressure hydrocephalus. Semin Neurol. 2007 Feb. 27(1):58-65. [Medline].

  33. Walter C, Hertel F, Naumann E, Morsdorf M. Alteration of cerebral perfusion in patients with idiopathic normal pressure hydrocephalus measured by 3D perfusion weighted magnetic resonance imaging. J Neurol. 2005 Dec. 252(12):1465-71. [Medline].

  34. Wikkelso C, Andersson H, Blomstrand C, Lindqvist G, Svendsen P. Normal pressure hydrocephalus. Predictive value of the cerebrospinal fluid tap-test. Acta Neurol Scand. 1986 Jun. 73(6):566-73. [Medline].

T2-weighted MRI showing dilatation of ventricles out of proportion to sulcal atrophy in a patient with normal pressure hydrocephalus. The arrow points to transependymal flow.
CT head scan of a patient with normal pressure hydrocephalus showing dilated ventricles. The arrow points to a rounded frontal horn.
This image shows ventriculomegaly, which is typical in hydrocephalus ex vacuo.
This image shows cortical atrophy, which is the defining feature of hydrocephalus ex vacuo.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.